News Pfizer will have to cut price of AML drug Mylotarg after NIC... NICE blocks access to 65% of patients on cost grounds
News NICE asks EUSA pharma to drop price of neuroblastoma drug NICE calls for price cut before possible CDF funding
News Report warns of UK's rare disease 'postcode lottery' There is still a ‘postcode lottery’ for patients getting access to vital rare disease treatments in the UK, according to a new report.
Market Access Row over CF drug funding as NHS rejects Vertex offer Vertex 'astonished and dismayed' by NHS rejection
News FDA clears first all-oral combo for first-line CLL treatment AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
